GlaxoSmithKline Pharmaceuticals Ltd. has signed a licensing agreement with Japanese pharma Astellas Pharma Inc., which will give it exclusive rights to Astellas's injectible anti-fungal agent, Micafungin, in India
The research-based pharmaceutical healthcare company GlaxoSmithKline (GSK) has tied up with Japanese company Astellas Pharma for exclusive rights of its research product by the brand name Mycamine. Micafungin provides an excellent fit with oncology where GSK has a promising R&D pipeline
GlaxoSmithKline Pharma is a 49 % subsidiary ofGlaxoSmithKline Plc (UK). Micafungin, an original research product of Astellas, was approved by the FDA in 2005.
The tie-up is to assert GSK's presence in the intensive care. The inject able anti-fungal agent Micafungin is approved by many countries across the world. Micafungin belongs to a new class of anti-fungal agents that work against deep-seated Candida infections.
The agreement is in line with the company's strategy to collaborate with global pharmaceutical companies for licensing in important molecules.